Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.
about
Antiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and PrognosisTreatment for hepatitis B in patients with drug resistanceTDF Monotherapy Is Effective Regardless of Prior Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Patients in China.Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C.Predictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.Prevalence of Hepatitis B and C Viral Infection Among Pregnant Women in Peshawar, PakistanPegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye.Hepatitis C virus treatment in the real world: optimising treatment and access to therapies.Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.Association of antiviral therapy with reduced disease progression in chronic Hepatitis B patients: Results from a nation-wide cohort study.Treatment of patients with dual hepatitis B and C: a step in the right direction.Commentary: absolute and relative contraindications to pegylated-interferon or ribavirin in the US general patient population with chronic hepatitis C.What do clinicians need to watch for with direct-acting antiviral therapy?Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection: combining evidence and common sense.
P2860
Q26740313-9D84BCC4-5A0C-4653-A969-6A457764F11BQ28072483-886D784F-4E6C-4C6F-A693-DE660C33D09BQ33800724-2C1A6D59-FF4B-4E9D-9838-0B157078930BQ33834742-521F87A5-0A3D-46CA-AAA2-D4EBAA85E991Q34684406-BB5D1FB8-6EFC-4183-B83C-D97A03A92107Q36699256-6A19D9C0-07CD-465B-B8E2-64D929800F57Q37232165-4DE9974D-3114-49F8-86EC-5F488AC4CFF6Q38102776-1996BEC8-A029-4EEF-81D1-5C66D44F881FQ38522791-AFC374D7-F109-4C11-94B3-84C78D7A3B57Q38602682-53731F86-30F7-4D03-B776-5B85896646BBQ41962614-31BA770A-5A1D-4E76-83BC-4B5AB7FFAC2EQ43516424-4F29788F-006C-423A-B46D-BD020B05192CQ44773881-F0308268-8312-45B5-B660-C2F4E23E3052Q46222665-418B81F3-1964-4D9B-920F-9338BC1BD697Q52327014-09FF25B3-E922-449B-B849-DC730D98908CQ54655936-24C37C14-D6F4-4616-B717-6420DCDDE3D1
P2860
Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Assessing long-term treatment ...... een evidence and common sense.
@en
type
label
Assessing long-term treatment ...... een evidence and common sense.
@en
prefLabel
Assessing long-term treatment ...... een evidence and common sense.
@en
P1476
Assessing long-term treatment ...... ween evidence and common sense
@en
P2093
Massimo Colombo
P304
P356
10.1016/J.JHEP.2012.06.025
P577
2012-06-28T00:00:00Z